Simon Drysdale
@sbdrysdale
More real-world data showing Nirsevimab is well accepted and efficacious!
It was >70% effective in preventing RSV LRTI hospitalisation in infants in 3 Spanish regions, where a universal immunisation programme began in late September 2023 (coverage:79–99%).
pubmed.ncbi.nlm.nih.gov/38333937/
It was >70% effective in preventing RSV LRTI hospitalisation in infants in 3 Spanish regions, where a universal immunisation programme began in late September 2023 (coverage:79–99%).
pubmed.ncbi.nlm.nih.gov/38333937/
pubmed.ncbi.nlm.nih.govEarly estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for...
0 9